Topic: liver disease

Intercept Pharmaceuticals | Obeticholic acid (OCA)

Intercept already sells obeticholic acid as Ocaliva for the treatment of primary biliary cholangitis; it earned the FDA nod for that liver disease back in 2016. Intercept submitted OCA for FDA approval in NASH in September and plans to follow up with a European Medicines Agency filing by the end of the year.